Clinical trial · Interventional
Radiofrequency Ablation Study in LatinX Patients
Study of the Use of Radiofrequency Ablation in LatinX Patients With Symptomatic Benign Thyroid Nodules
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Benign thyroid nodules can still create cosmetic, compressive, or hormonal issues for patients. In the past, surgery was typically used to treat thyroid nodules causing the above issues through partial or complete thyroidectomy. More recently, minimally-invasive techniques have been developed to treat these issues. This study is investigating the use of one of these techniques, radiofrequency ablation, in Latinx patients with benign symptomatic thyroid nodules. This procedure is of interest because it avoids the risks of surgery and can be done outside an operating room. The study hypothesis is that the use of RFA is an effective and safe therapeutic option for LatinX patients with a symptomatic benign nodule wishing to avoid surgery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thyroid Nodule | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Mygen V-1000 RF system | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Mygen V-1000 RF system
- description
- The Mygen V-1000, a microprocessor-based generator of RF Medical Co., Ltd., provides up to 140 watts of radio-frequency (RF) energy to be used for coagulation \& ablation of vessel, tissue \& bone
- interventionNames
- Device: Mygen V-1000 RF system
Primary outcomes (1)
- measure
- Number of participants with treatment-related changes in thyroid nodule volumes
- timeFrame
- 2 years
- description
- To study the change in nodule volume
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Subject capable of giving informed consent * Stated willingness to comply with all study procedures and availability for the duration of the study * Subjects over 18 years of age * Subject who self-identifies as LatinX * Subjects who have a benign, symptomatic thyroid nodule * Subjects whose nodule has well-defined margin on ultrasound and is surrounded by at least 2mm of normal thyroid parenchyma in all directions Exclusion Criteria: * Patients who are pregnant, trying to become pregnant, or breastfeeding * Patient who have a cardiac pacemaker,defibrillator , or other electromedical equipment * Patients who have a nodule that is malignant or not predominantly solid (must be \>50% solid by ultrasound) * Patients who cannot give consent * Patients on anticoagulation or dual antiplatelet therapy * Patients with acute illness * People with BP \> 140/90 prior to the scheduled procedure
References
Publications (0)
Data not yet available